Lisdexamfetamine for the Improvement of Executive Function in Women who have Undergone Risk-Reducing Bilateral Salpingo-Oophorectomy, IMPRES Study

Inclusion Criteria

• Females aged 35 to 58 years.
• Have undergone risk-reducing bilateral salpingo-oophorectomy (RRSO) within the previous 15 years and were premenopausal at the time of RRSO.
• Score of >= 20 on the Brown Attention Deficit Disorder Scale (BADDS).
• Onset of executive function difficulties occurred post RRSO.
• Clean urine drug screen (nicotine and marijuana are permissible). Potential false-positive screenings will be reviewed and exclusionary based on primary investigator (PI) discretion.
• Are fluent in written and spoken English.
• Are able to give written informed consent (obtained at screening visit).
• Have a high school diploma or equivalent degree (i.e., General Equivalency Diploma [GED]), as per subject report.
• If using aromatase inhibitors or tamoxifen: Must have been on a stable dose for at least 6 months.
• If completing visits remotely: Must have access to a telecommunications application (i.e., Skype), email, scanner/fax machine, and a private area that enables the protection of participant confidentiality.

Exclusion Criteria

• Current untreated psychiatric disorder.
• Substance use disorder within the previous 3 years.
• Lifetime history of attention deficit hyperactivity disorder (ADHD) or psychotic disorder including bipolar disorder, schizoaffective disorder, and schizophrenia.
• Lifetime history of stimulant abuse or dependence.
• Regular use of psychotropic medications except selective serotonin reuptake inhibitors (SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), bupropion, zolpidem, gabapentin, or buspirone.
• Chemotherapy within the past year.
• Previous history of sensitivity or adverse reaction to lisdexamfetamine (LDX).
• History of seizures or unstable medical condition.
• Known heart disease or clinically significant abnormal electrocardiogram during screening as determined by the study medical doctor (MD).
• Uncontrolled hypertension.
• Presence of a metallic implant contraindicative to scanning at the 7T level.
• Claustrophobia.
• Consistent systolic blood pressure of > 145 mm Hg or diastolic blood pressure > 90 mm Hg after three readings at time of screening.
• Known renal impairment and end stage renal disease (ESRD).